Anglo-US biotech NodThera has named former Jazz Pharma executive Dan Swisher as its new chief executive, replacing Alan Watt, who will take on the dual roles of president
Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other di
Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up